HCWB - hcwbiologics.com Debt to Book Capitalization Ratio

Graphic logo of HCW Biologics (HCWB)

HCW Biologics Inc. (HCWB) management, led by Hing Wong, is betting on advanced immunotherapy by attracting external investments. The ratio of debt to book capitalization demonstrates the debt load dynamics, where 0.87 represents the current level of the metric. Effective production outsourcing reduces operational risks, although global component logistics from Asia remain a sensitive factor.

HCWB (HCW Biologics) Debt to Book Value history from 07/04/2022 to 10/28/2026
Core merchandise of hcwbiologics.com

The development of protein therapies via the TOPO platform requires colossal R&D expenditures, which directly impacts the financing structure of HCW Biologics Inc. (HCWB). This indicator measures the ratio of total liabilities to equity, reflecting the actual debt load. The metric allows for an assessment of the company's ability to replace borrowed funds with equity during periods of high volatility. Reducing leverage minimizes bankruptcy risks, although excessive conservatism may limit the pace of innovation. Correlating the size of debt with balance sheet equity objectively captures the financial stability of the business.

Who HCW Biologics Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization Immunome Corp (IMNM)|GOSS - Debt to Net Assets Ratio|KALV (KalVista Pharmaceuticals) - Debts to Book Capitalization|Debt to Book Value septerna.com|Debt to Book Value PVLA|Debt to Book Value Savara Inc (SVRA)|Rigel Pharmaceuticals Inc (RIGL) - Debt to Book Value|Debt to Net Assets Ratio AnaptysBio Inc. (ANAB)|Debts to Book Capitalization Astria Therapeutics ATXS|Debt to Book Capitalization Ratio engene.com ENGN|Debts to Book Capitalization RAPT (RAPT Therapeutics, Inc.)|JBIO: Debts to Net Assets|Debt to Book Capitalization Ratio ACRS|KYTX (Kyverna Therapeutics, Inc) - Debts to Book Value|Debt to Book Capitalization Ratio Tiziana Life Sciences|Debt to Book Capitalization Ratio CABA|Ventyx Biosciences, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value Theratechnologies, Inc. (THTX)|AVTX (Avalo Therapeutics Inc.) - Debts to Book Capitalization|Debt to Net Assets Eledon Pharmaceuticals, Inc ELDN|Debts to Book Capitalization AGEN (Agenus)|CLYM - Debts to Net Assets|ZURA (Zura Bio Limited) - Debts to Book Capitalization|ATYR (aTyr Pharma Inc) - Debt to Book Value|ADAG: Debt to Book Capitalization Ratio|Debts to Net Assets Ikena Oncology, Inc. (IMA)|Shattuck Labs, Inc. (STTK) - Debt to Book Value|Debt to Net Assets Ratio equilliumbio.com (EQ)|Debts to Book Capitalization CNTB|Immunic Therapeutics - Debts to Net Assets|Atara Biotherapeutics Inc (ATRA) - Debt to Book Capitalization Ratio|IFRX - Debt to Book Value Ratio|XFOR (X4 Pharmaceuticals) - Debts to Book Capitalization|Debt to Book Value Adicet Bio, Inc.|CELU: Debt to Book Value|Debts to Net Assets INmune Bio Inc|Barinthus Bio (BRNS) - Debts to Book Capitalization|Debt to Net Assets Ratio Kezar Life Sciences Inc (KZR)|SAB Biotherapeutics - Debts to Book Capitalization|AKTX - Debt to Book Value|ENLV: Debt to Book Value|QTTB - Debt to Book Value|GeoVax Labs Inc (GOVX) - Debts to Book Capitalization|EDSA (Edesa Biotech Corp) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio iBio, Inc. IBIO|Debts to Book Capitalization Ratio Carisma Tx|XTL Biopharmaceuticals Ltd. (XTLB) - Debts to Book Capitalization|Debt to Net Assets Ratio boltbio.com (BOLT)|Debts to Book Capitalization APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio Aditxt Corp (ADTX)|GRI: Debt to Net Assets Ratio|XRTX (XORTX Therapeutics) - Debt to Book Capitalization Ratio|Vyome Holdings Inc. (HIND) - Debt to Book Value|REVB (Revelation Bio) - Debts to Book Capitalization|Debts to Book Capitalization Indaptus Corp (INDP)|Scinai Immunotherapeutics (SCNI) - Debt to Book Value|Debt to Net Assets Ratio calcimedica.com (CALI)|Debts to Book Capitalization AFMD|Allakos Inc - Debts to Net Assets|HOOK: Debt to Book Capitalization Ratio|IGMS: Debt to Book Value|ITOS (iTeos Therapeutics) - Debt to Book Capitalization Ratio|Debt to Book Value oceanbiomedical.com|TCBP (TC BioPharm) - Debt to Book Value|Debts to Book Capitalization THRD